Check out the latest articles and abstracts on acute myeloid leukemia (AML), leukemia stem cells, PARP inhibitors, DNA repair, and more from Dr. Wang’s team.
Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches
Leukemia & Lymphoma, April 2022
We demonstrate that combining an innate immune agonist with a checkpoint inhibitor synergistically improved anti-tumor activity in a preclinical AML model.
- Authors: Przespolewski AC, Portwood S, Wang ES.
- Citation: Leuk Lymphoma. 2022 Apr;63(4):918-927. doi: 10.1080/10428194.2021.1992614. Epub 2021 Nov 25. PMID: 34818963.
Menin Inhibitors in Acute Myeloid Leukemia: What Does the Future Hold?
Cancer Journal, January-February 2022
This review details the current clinical experience of menin inhibitors in AML and discusses how these agents can be successfully integrated into future therapeutic approaches.
- Authors: Swaminathan M, Bourgeois W, Armstrong SA, Wang ES.
- Citation: Cancer J. 2022 Jan-Feb 01;28(1):62-66. doi: 10.1097/PPO.0000000000000571. PMID: 35072375.
More 2022 publications
Tsai HK, et al. Allelic Complexity of KMT2A Partial Tandem Duplications in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Blood Adv. 2022 May 18:bloodadvances.2022007613. doi: 10.1182/bloodadvances.2022007613. Epub ahead of print. PMID: 35584376.
Murdock HM, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients. Blood. 2022 Mar 14:blood.2021014520. doi: 10.1182/blood.2021014520. Epub ahead of print. PMID: 35286378.
Versluis J, et al. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Adv. 2022 May 10;6(9):2835-2846. doi: 10.1182/bloodadvances.2021006166. PMID: 35081257; PMCID: PMC9092400.
Perl AE, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. PMID: 35081255.
Schaefer EJ, et al. BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood Cancer Discov. 2022 Mar 1;3(2):116-135. doi: 10.1158/2643-3230.BCD-21-0115. PMID: 35015684.
Connect with the Wang Lab
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263